It's only natural for stocks to take a breather after a big up-day. That's exactly what's happening today, as many start to wonder if the nearly 13% rise in the S&P 500 we've seen so far in 2012 really leaves room for further gains. As of around 1:45 p.m. EDT, the Dow Jones Industrials (INDEX: ^DJI) were down nine points to 13,232, while the S&P 500 was just above the unchanged mark at 1,417.

Among Dow stocks, Pfizer (NYSE: PFE) soared more than 1.5% on speculation that the company will not only sell off parts of its business but also split its remaining segments into multiple companies via spinoffs. Comparing the situation to the breakup that Abbott Labs (NYSE: ABT) is in the process of doing, analysts at Goldman Sachs released a report suggesting that Pfizer could be more aggressive in restructuring itself. Lately, it seems that a number of stocks across various industries are turning to spinoffs as a way to unlock shareholder value.

DuPont (NYSE: DD) rose about 0.5%. Brazilian agriculture company Camera Agroalimentos announced plans to build a biodiesel chemical plant in its home country for about $11 million. The company plans to buy needed sodium from DuPont. Although the move is obviously a small one, the growing biodiesel movement could spell an opportunity for the chemical maker to move more strongly into the alternative energy industry.

Finally, Coca-Cola (NYSE: KO) was roughly unchanged in afternoon trading. An interesting article in Forbes compared cola companies in the U.S. to cigarette companies, as they've been facing lower volumes and answering by offering higher-margin products. Unlike many tobacco companies, though, Coke has international expansion opportunities that should help boost profits well into the future.

Think long-term
Even when the Dow goes nowhere, great stocks can provide good returns over time. Learn about the one stock the Fool's chief investment officer picked to crush the market in this free report: "The Motley Fool's Top Stock for 2012." Instant access is just a click away.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.